Global Preclinical CRO Market by Service (Bioanalysis & DMPK Studies, Toxicology Testing), by End Use (Government & Academic Institutes, Biopharmaceutical Companies) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global preclinical CRO market was valued at USD4.5 billion in 2020. It is projected to grow at 8.1% compound annual growth rate (CAGR), between 2021 and 2028. The market growth is expected to be boosted by an increase in R&D budgets for drug development. Preclinical research projects have been disrupted by the ongoing COVID-19 pandemic, particularly in the first quarter 2020. However, lifesaving drugs will be quickly developed and put on the market. The preclinical CROs play a crucial role in the commercialization of the idea for different biopharmaceutical companies.
The preclinical trials for the COVID-19 vaccine have been completed at an incredible pace, a sign of the immense role played by CROs. The market is expected to grow significantly if CRO services are more widely used. Servier Research Institute's 2017 survey found that around half of all preclinical failures are due to toxicology testing. This will increase the demand for CRO services in the future. Recent regulatory changes in Europe regarding preclinical CRO service are expected to also increase demand for toxicology testing and contribute to regional market growth.
The process for drug approval by FDA has seen significant changes over the years. The 21st Century Cures Act was recently passed in the United States. This bill accelerated the approval process for medical devices and breakthrough drugs. These changes to approval procedures are expected to spur innovation and increase demand for preclinical services. This will contribute to market growth.
Impact of COVID19: Bioanalysis and DMPK Studies saw the fastest growth rate at 8.6% in 2020
|
Pandemic Impact |
Outlook after COVID |
|
The wider industry had an impact on drug research and development, with many companies having to stop or delay programs. This is true for both the larger pharma companies and smaller virtual companies that don't have clinical data. |
It has been possible to develop accelerated paths for antivirals and immunomodulators and anticoagulants. These can be used as ''roadmaps" to help prioritize compounds for clinical testing. |
|
The new COVID-19 vaccine candidate has been developed by researchers at the Cleveland Clinic's Global Center for Pathogen Research & Human Health. It uses nanotechnology and has proven to be highly effective in preclinical models of disease. |
As companies consider R&D, the debate between efficiency and resilience will be key. For example, rebalancing research work across countries by contract research organisations (CROs), or evaluating clinical supply chain diversification in order to minimize vulnerabilities. |
|
The global COVID-19 vaccine research and development landscape currently includes 115 vaccine candidates. 78 of these vaccine candidates have been confirmed active, while 37 remain unconfirmed. Out of the 78 active projects, 73 remain in exploratory or preclinical stage. |
Preclinical trials are ongoing. They will continue for the next few months to determine if MRT5500 and additional mRNA vaccine candidate candidates will induce neutralizing antibodies to the emerging SARS CoV-2 variants. This could inform future clinical development. |
Preclinical CROs are not compliant with international regulations, such as Good Laboratory Practice standards (GLP), which can lead to quality problems. Biopharmaceutical companies and medical device firms generally outsource low-end preclinical trial functions to CROs. High-end tests such as genotoxicity are usually performed in-house. The CROs are expected to improve their quality standards. Outsourced vendors currently try to adhere to the international standards established by regulatory authorities such as the U.S. FDA (US) and the European Medicines Agency, (EMA).
Service Insights
The market can be divided into several service segments: bioanalysis and DMPK, toxicology testing and compound management. Safety pharmacology and chemistry are also included. In 2020, the toxicology testing segment was the most lucrative with a more than 22% revenue share. This is due to increased outsourcing of preclinical CRO studies as well as high adoption of toxicology tests.
The segment of bioanalysis and DMPK analyses is expected to grow at 8.4% CAGR over the forecast period. This segment will experience lucrative growth due to a rising demand for pharmacokinetic support for toxicology tests for IND-enabling research. Bioanalysis and DMPK are essential in drug development. These studies are done at every stage of drug development and not just in the preclinical phase.
End-use Type Insights
In 2020, the market share for biopharmaceutical businesses will exceed 80%. Preclinical CRO services will be in demand due to the increasing trend in outsourcing services from biopharmaceutical firms, particularly among small and medium-sized companies lacking sufficient expertise in drug development.
According to forecasts, the fastest growth will be seen in the government and academic institutions segment. Preclinical discovery and development is a critical phase in which government and academia play an important role. The segment will also grow as more academic institutions and government agencies outsource preclinical services for CROs. For large CROs like Charles River Laboratories or LabCorp, academic institutes are a major source of revenue.
Regional Insight
North America was the dominant market place in 2020, accounting for more than 47% of the total revenue. Due to increased R&D spending and the high adoption of new technology, the region will continue to be dominant over the forecast period. Market growth will also be driven by the availability of skilled workers and the low cost of devices.
Due to increasing rates of chronic diseases, the demand for preclinical services in CRO is also growing. Asia Pacific will experience the fastest CAGR during the forecast period. This is due to the cost-efficiency and efficiency of preclinical CROs located in countries such as India or China. The preclinical outsourcing market for Asia Pacific has been strengthened by the establishment of multiple CROs. Singapore, for example, has many CROs that can support growing pharmaceutical and biopharmaceutical company needs.
Market Share Insights & Key Companies
The rapid adoption of new healthcare technologies is one of the key factors driving market competition. To retain market share and diversify their product portfolio, major players are launching new products and completing mergers and acquisitions. The market leaders are providing support and services in the face of the coronavirus pandemic. Parexel and Innoplexus collaborated to launch the COVID-19 Clearinghouse in September 2020. This online resource allows researchers, patients, and sponsors of clinical trials to access data, publications, current news, and links to active clinical trials. These are some of the major companies that make up the preclinical CRO market:
-
Envigo Corp.
-
MPI Research
-
Eurofins Scientific
-
PRA Health Sciences, Inc.
-
Wuxi AppTec
-
Medpace, Inc.
-
Pharmaceutical Product Development (PPD), LLC
-
PARAXEL International Corp.
-
ICON Plc
-
Laboratory Corporation of America, Inc.
Up Market Research published a new report titled “Preclinical CRO Market research report which is segmented by Service (Bioanalysis & DMPK Studies, Toxicology Testing), by End Use (Government & Academic Institutes, Biopharmaceutical Companies), By Players/Companies LLC; PARAXEL International Corporation; ICON Plc; and Laboratory Corporation of America, Inc; Pharmaceutical Product Development (PPD), Inc; Wuxi AppTec; Medpace, Inc, Envigo Corporation; MPI research; Eurofins Scientific; PRA Health Sciences”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Preclinical CRO Market Research Report |
| By Service | Bioanalysis & DMPK Studies, Toxicology Testing |
| By End Use | Government & Academic Institutes, Biopharmaceutical Companies |
| By Companies | LLC; PARAXEL International Corporation; ICON Plc; and Laboratory Corporation of America, Inc; Pharmaceutical Product Development (PPD), Inc; Wuxi AppTec; Medpace, Inc, Envigo Corporation; MPI research; Eurofins Scientific; PRA Health Sciences |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 209 |
| Number of Tables & Figures | 147 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Preclinical CRO Market Report Segments:
The market is segmented by Service (Bioanalysis & DMPK Studies, Toxicology Testing), by End Use (Government & Academic Institutes, Biopharmaceutical Companies).
Preclinical CRO Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Preclinical CRO Market
Overview of the regional outlook of the Preclinical CRO Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Preclinical CRO Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Preclinical CRO Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Bioanalysis & DMPK Studies
2. Toxicology Testing
7. By End Use:1. Government & Academic Institutes
2. Biopharmaceutical Companies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Preclinical CRO Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Preclinical CRO Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Preclinical CRO Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Preclinical CRO Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Preclinical CRO Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Preclinical CRO Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Preclinical CRO Market Size & Forecast, 2018-2028
4.5.1 Preclinical CRO Market Size and Y-o-Y Growth
4.5.2 Preclinical CRO Market Absolute $ Opportunity
Chapter 5 Global Preclinical CRO Market Analysis and Forecast by Service
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Service
5.1.2 Basis Point Share (BPS) Analysis by Service
5.1.3 Absolute $ Opportunity Assessment by Service
5.2 Preclinical CRO Market Size Forecast by Service
5.2.1 Bioanalysis & DMPK Studies
5.2.2 Toxicology Testing
5.3 Market Attractiveness Analysis by Service
Chapter 6 Global Preclinical CRO Market Analysis and Forecast by End Use
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End Use
6.1.2 Basis Point Share (BPS) Analysis by End Use
6.1.3 Absolute $ Opportunity Assessment by End Use
6.2 Preclinical CRO Market Size Forecast by End Use
6.2.1 Government & Academic Institutes
6.2.2 Biopharmaceutical Companies
6.3 Market Attractiveness Analysis by End Use
Chapter 7 Global Preclinical CRO Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Preclinical CRO Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Preclinical CRO Analysis and Forecast
9.1 Introduction
9.2 North America Preclinical CRO Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Preclinical CRO Market Size Forecast by Service
9.6.1 Bioanalysis & DMPK Studies
9.6.2 Toxicology Testing
9.7 Basis Point Share (BPS) Analysis by Service
9.8 Absolute $ Opportunity Assessment by Service
9.9 Market Attractiveness Analysis by Service
9.10 North America Preclinical CRO Market Size Forecast by End Use
9.10.1 Government & Academic Institutes
9.10.2 Biopharmaceutical Companies
9.11 Basis Point Share (BPS) Analysis by End Use
9.12 Absolute $ Opportunity Assessment by End Use
9.13 Market Attractiveness Analysis by End Use
Chapter 10 Europe Preclinical CRO Analysis and Forecast
10.1 Introduction
10.2 Europe Preclinical CRO Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Preclinical CRO Market Size Forecast by Service
10.6.1 Bioanalysis & DMPK Studies
10.6.2 Toxicology Testing
10.7 Basis Point Share (BPS) Analysis by Service
10.8 Absolute $ Opportunity Assessment by Service
10.9 Market Attractiveness Analysis by Service
10.10 Europe Preclinical CRO Market Size Forecast by End Use
10.10.1 Government & Academic Institutes
10.10.2 Biopharmaceutical Companies
10.11 Basis Point Share (BPS) Analysis by End Use
10.12 Absolute $ Opportunity Assessment by End Use
10.13 Market Attractiveness Analysis by End Use
Chapter 11 Asia Pacific Preclinical CRO Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Preclinical CRO Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Preclinical CRO Market Size Forecast by Service
11.6.1 Bioanalysis & DMPK Studies
11.6.2 Toxicology Testing
11.7 Basis Point Share (BPS) Analysis by Service
11.8 Absolute $ Opportunity Assessment by Service
11.9 Market Attractiveness Analysis by Service
11.10 Asia Pacific Preclinical CRO Market Size Forecast by End Use
11.10.1 Government & Academic Institutes
11.10.2 Biopharmaceutical Companies
11.11 Basis Point Share (BPS) Analysis by End Use
11.12 Absolute $ Opportunity Assessment by End Use
11.13 Market Attractiveness Analysis by End Use
Chapter 12 Latin America Preclinical CRO Analysis and Forecast
12.1 Introduction
12.2 Latin America Preclinical CRO Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Preclinical CRO Market Size Forecast by Service
12.6.1 Bioanalysis & DMPK Studies
12.6.2 Toxicology Testing
12.7 Basis Point Share (BPS) Analysis by Service
12.8 Absolute $ Opportunity Assessment by Service
12.9 Market Attractiveness Analysis by Service
12.10 Latin America Preclinical CRO Market Size Forecast by End Use
12.10.1 Government & Academic Institutes
12.10.2 Biopharmaceutical Companies
12.11 Basis Point Share (BPS) Analysis by End Use
12.12 Absolute $ Opportunity Assessment by End Use
12.13 Market Attractiveness Analysis by End Use
Chapter 13 Middle East & Africa (MEA) Preclinical CRO Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Preclinical CRO Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Preclinical CRO Market Size Forecast by Service
13.6.1 Bioanalysis & DMPK Studies
13.6.2 Toxicology Testing
13.7 Basis Point Share (BPS) Analysis by Service
13.8 Absolute $ Opportunity Assessment by Service
13.9 Market Attractiveness Analysis by Service
13.10 Middle East & Africa (MEA) Preclinical CRO Market Size Forecast by End Use
13.10.1 Government & Academic Institutes
13.10.2 Biopharmaceutical Companies
13.11 Basis Point Share (BPS) Analysis by End Use
13.12 Absolute $ Opportunity Assessment by End Use
13.13 Market Attractiveness Analysis by End Use
Chapter 14 Competition Landscape
14.1 Preclinical CRO Market: Competitive Dashboard
14.2 Global Preclinical CRO Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 LLC; PARAXEL International Corporation; ICON Plc; and Laboratory Corporation of America
14.3.2 Inc; Pharmaceutical Product Development (PPD)
14.3.3 Inc; Wuxi AppTec; Medpace
14.3.4 Inc
14.3.5 Envigo Corporation; MPI research; Eurofins Scientific; PRA Health Sciences
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Preclinical CRO Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Preclinical CRO Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Preclinical CRO Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Preclinical CRO Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Preclinical CRO Market Size & Forecast, 2018-2028
4.5.1 Preclinical CRO Market Size and Y-o-Y Growth
4.5.2 Preclinical CRO Market Absolute $ Opportunity
Chapter 5 Global Preclinical CRO Market Analysis and Forecast by Service
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Service
5.1.2 Basis Point Share (BPS) Analysis by Service
5.1.3 Absolute $ Opportunity Assessment by Service
5.2 Preclinical CRO Market Size Forecast by Service
5.2.1 Bioanalysis & DMPK Studies
5.2.2 Toxicology Testing
5.3 Market Attractiveness Analysis by Service
Chapter 6 Global Preclinical CRO Market Analysis and Forecast by End Use
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by End Use
6.1.2 Basis Point Share (BPS) Analysis by End Use
6.1.3 Absolute $ Opportunity Assessment by End Use
6.2 Preclinical CRO Market Size Forecast by End Use
6.2.1 Government & Academic Institutes
6.2.2 Biopharmaceutical Companies
6.3 Market Attractiveness Analysis by End Use
Chapter 7 Global Preclinical CRO Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Preclinical CRO Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Preclinical CRO Analysis and Forecast
9.1 Introduction
9.2 North America Preclinical CRO Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Preclinical CRO Market Size Forecast by Service
9.6.1 Bioanalysis & DMPK Studies
9.6.2 Toxicology Testing
9.7 Basis Point Share (BPS) Analysis by Service
9.8 Absolute $ Opportunity Assessment by Service
9.9 Market Attractiveness Analysis by Service
9.10 North America Preclinical CRO Market Size Forecast by End Use
9.10.1 Government & Academic Institutes
9.10.2 Biopharmaceutical Companies
9.11 Basis Point Share (BPS) Analysis by End Use
9.12 Absolute $ Opportunity Assessment by End Use
9.13 Market Attractiveness Analysis by End Use
Chapter 10 Europe Preclinical CRO Analysis and Forecast
10.1 Introduction
10.2 Europe Preclinical CRO Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Preclinical CRO Market Size Forecast by Service
10.6.1 Bioanalysis & DMPK Studies
10.6.2 Toxicology Testing
10.7 Basis Point Share (BPS) Analysis by Service
10.8 Absolute $ Opportunity Assessment by Service
10.9 Market Attractiveness Analysis by Service
10.10 Europe Preclinical CRO Market Size Forecast by End Use
10.10.1 Government & Academic Institutes
10.10.2 Biopharmaceutical Companies
10.11 Basis Point Share (BPS) Analysis by End Use
10.12 Absolute $ Opportunity Assessment by End Use
10.13 Market Attractiveness Analysis by End Use
Chapter 11 Asia Pacific Preclinical CRO Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Preclinical CRO Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Preclinical CRO Market Size Forecast by Service
11.6.1 Bioanalysis & DMPK Studies
11.6.2 Toxicology Testing
11.7 Basis Point Share (BPS) Analysis by Service
11.8 Absolute $ Opportunity Assessment by Service
11.9 Market Attractiveness Analysis by Service
11.10 Asia Pacific Preclinical CRO Market Size Forecast by End Use
11.10.1 Government & Academic Institutes
11.10.2 Biopharmaceutical Companies
11.11 Basis Point Share (BPS) Analysis by End Use
11.12 Absolute $ Opportunity Assessment by End Use
11.13 Market Attractiveness Analysis by End Use
Chapter 12 Latin America Preclinical CRO Analysis and Forecast
12.1 Introduction
12.2 Latin America Preclinical CRO Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Preclinical CRO Market Size Forecast by Service
12.6.1 Bioanalysis & DMPK Studies
12.6.2 Toxicology Testing
12.7 Basis Point Share (BPS) Analysis by Service
12.8 Absolute $ Opportunity Assessment by Service
12.9 Market Attractiveness Analysis by Service
12.10 Latin America Preclinical CRO Market Size Forecast by End Use
12.10.1 Government & Academic Institutes
12.10.2 Biopharmaceutical Companies
12.11 Basis Point Share (BPS) Analysis by End Use
12.12 Absolute $ Opportunity Assessment by End Use
12.13 Market Attractiveness Analysis by End Use
Chapter 13 Middle East & Africa (MEA) Preclinical CRO Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Preclinical CRO Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Preclinical CRO Market Size Forecast by Service
13.6.1 Bioanalysis & DMPK Studies
13.6.2 Toxicology Testing
13.7 Basis Point Share (BPS) Analysis by Service
13.8 Absolute $ Opportunity Assessment by Service
13.9 Market Attractiveness Analysis by Service
13.10 Middle East & Africa (MEA) Preclinical CRO Market Size Forecast by End Use
13.10.1 Government & Academic Institutes
13.10.2 Biopharmaceutical Companies
13.11 Basis Point Share (BPS) Analysis by End Use
13.12 Absolute $ Opportunity Assessment by End Use
13.13 Market Attractiveness Analysis by End Use
Chapter 14 Competition Landscape
14.1 Preclinical CRO Market: Competitive Dashboard
14.2 Global Preclinical CRO Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 LLC; PARAXEL International Corporation; ICON Plc; and Laboratory Corporation of America
14.3.2 Inc; Pharmaceutical Product Development (PPD)
14.3.3 Inc; Wuxi AppTec; Medpace
14.3.4 Inc
14.3.5 Envigo Corporation; MPI research; Eurofins Scientific; PRA Health Sciences
Segments Covered in the Report
The global Preclinical CRO market has been segmented based on
By Service
The global Preclinical CRO market has been segmented based on
By Service
- Bioanalysis & DMPK Studies
- Toxicology Testing
- Government & Academic Institutes
- Biopharmaceutical Companies
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- LLC; PARAXEL International Corporation; ICON Plc; and Laboratory Corporation of America
- Inc; Pharmaceutical Product Development (PPD)
- Inc; Wuxi AppTec; Medpace
- Inc
- Envigo Corporation; MPI research; Eurofins Scientific; PRA Health Sciences
Our Clients
Related Reports
Some other reports from this category!
